These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 29381098)

  • 21. Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
    Albitar A; Ma W; DeDios I; Estella J; Ahn I; Farooqui M; Wiestner A; Albitar M
    Oncotarget; 2017 Mar; 8(11):17936-17944. PubMed ID: 28212557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
    Woyach JA; Jones D; Jurczak W; Robak T; Illés Á; Kater AP; Ghia P; Byrd JC; Seymour JF; Long S; Mohamed N; Benrashid S; Lai TH; De Jesus G; Lai R; de Bruin G; Rule S; Munugalavadla V
    Blood; 2024 Sep; 144(10):1061-1068. PubMed ID: 38754046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
    Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
    Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
    Lama TG; Kyung D; O'Brien S
    Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
    Burger JA; Landau DA; Taylor-Weiner A; Bozic I; Zhang H; Sarosiek K; Wang L; Stewart C; Fan J; Hoellenriegel J; Sivina M; Dubuc AM; Fraser C; Han Y; Li S; Livak KJ; Zou L; Wan Y; Konoplev S; Sougnez C; Brown JR; Abruzzo LV; Carter SL; Keating MJ; Davids MS; Wierda WG; Cibulskis K; Zenz T; Werner L; Dal Cin P; Kharchencko P; Neuberg D; Kantarjian H; Lander E; Gabriel S; O'Brien S; Letai A; Weitz DA; Nowak MA; Getz G; Wu CJ
    Nat Commun; 2016 May; 7():11589. PubMed ID: 27199251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
    Saba NS; Wong DH; Tanios G; Iyer JR; Lobelle-Rich P; Dadashian EL; Liu D; Fontan L; Flemington EK; Nichols CM; Underbayev C; Safah H; Melnick A; Wiestner A; Herman SEM
    Cancer Res; 2017 Dec; 77(24):7038-7048. PubMed ID: 28993409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
    Ayed AO; Parikh SA
    Leuk Lymphoma; 2018 Oct; 59(10):2287-2296. PubMed ID: 29115892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How I manage ibrutinib-refractory chronic lymphocytic leukemia.
    Woyach JA
    Blood; 2017 Mar; 129(10):1270-1274. PubMed ID: 28096090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
    Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
    Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
    Wu J; Zhang M; Liu D
    Oncotarget; 2017 Jan; 8(4):7201-7207. PubMed ID: 27776353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
    Landau DA; Sun C; Rosebrock D; Herman SEM; Fein J; Sivina M; Underbayev C; Liu D; Hoellenriegel J; Ravichandran S; Farooqui MZH; Zhang W; Cibulskis C; Zviran A; Neuberg DS; Livitz D; Bozic I; Leshchiner I; Getz G; Burger JA; Wiestner A; Wu CJ
    Nat Commun; 2017 Dec; 8(1):2185. PubMed ID: 29259203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
    Woyach JA; Ghia P; Byrd JC; Ahn IE; Moreno C; O'Brien SM; Jones D; Cheung LWK; Chong E; Kwei K; Dean JP; James DF; Wiestner A
    Clin Cancer Res; 2023 Aug; 29(16):3065-3073. PubMed ID: 37314786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.
    Takács F; Kotmayer L; Czeti Á; Szalóki G; László T; Mikala G; Márk Á; Masszi A; Farkas P; Plander M; Weisinger J; Demeter J; Fekete S; Szerafin L; Deák BM; Szaleczky E; Sulák A; Borbényi Z; Barna G
    Pathol Oncol Res; 2022; 28():1610659. PubMed ID: 36213161
    [No Abstract]   [Full Text] [Related]  

  • 37. Oncogenic MTOR Signaling Axis Compensates BTK Inhibition in a Chronic Lymphocytic Leukemia Patient with Richter Transformation: A Case Report and Review of the Literature.
    Parigger T; Drothler S; Scherhäufl C; Gassner FJ; Schubert M; Steiner M; Höpner JP; Hödlmoser A; Schultheis L; Bakar AA; Neureiter D; Pleyer L; Egle A; Greil R; Geisberger R; Zaborsky N
    Acta Haematol; 2024; 147(5):604-611. PubMed ID: 38402867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
    Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
    Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
    Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting BTK through microRNA in chronic lymphocytic leukemia.
    Bottoni A; Rizzotto L; Lai TH; Liu C; Smith LL; Mantel R; Reiff S; El-Gamal D; Larkin K; Johnson AJ; Lapalombella R; Lehman A; Plunkett W; Byrd JC; Blachly JS; Woyach JA; Sampath D
    Blood; 2016 Dec; 128(26):3101-3112. PubMed ID: 27756747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.